Results 81 to 90 of about 169,757 (284)

ZNF224 enhances the oncogenic function of p21 via p53 and AKT pathways in melanoma

The FEBS Journal, EarlyView.
KRAB zinc finger protein ZNF224 acts as an oncogenic factor in melanoma cells, enhancing p21 cytosolic retention and impairing nuclear p21 cytostatic activity through stimulation of the AKT pathway. Furthermore, ZNF224 regulates transcriptional expression levels of p21 via p53.
Leandra Sepe, Umberto Candia, Dario Sasso del Verme, Elvira Toscano, Marianna Toriello, Gaetano Sodaro, Roberta Rapuano, Simona Romano, Michela Grosso, Giovanni Paolella, Angelo Lupo, Paola Costanzo, Elena Cesaro   +12 more
wiley   +1 more source

Chloroma of the Testis After Allogeneic Peripheral Blood Stem Cell Transplantation: A Case Report

Kaohsiung Journal of Medical Sciences, 2004
Chloroma, or granulocytic sarcoma, is a rare extramedullary solid hematologic cancer that affects many sites, usually in concert with acute myeloid leukemia.
Shih-Wen Hu, Sheau-Fang Yang, Chee-Yin Chai   +2 more
doaj   +1 more source

Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance. [PDF]

, 2017
The effect of prior malignancy on the risk of developing, and prognosis of, acute lymphoblastic leukemia (ALL) is unknown. This observational study utilized the California Cancer Registry to estimate the risk of developing ALL after a prior malignancy ...
Brunson, A, Jonas, BA, Keegan, THM, Paulus, JK, Rosenberg, AS, Tuscano, J, Wun, T   +6 more
core   +2 more sources

How I Approach Ethical Considerations for Pediatric Phase I CAR T‐Cell Trials

Pediatric Blood &Cancer, Volume 72, Issue 8, August 2025.
ABSTRACT Phase I trials of chimeric antigen receptor (CAR) T cells have shown remarkable promise in pediatric B‐cell malignancies. Such outcomes have shifted expectations for other phase I CAR T‐cell trials to have high response rates. The juxtaposition of high expectations, uncertain outcomes, and potential for life‐threatening toxicities raises ...
Sarah W. Peters, Sara K. Silbert, Elizabeth M. Holland, Annette Rid, Rayne H. Rouce, Christine Grady, Nirali N. Shah   +6 more
wiley   +1 more source

Targeting self-renewal pathways in myeloid malignancies [PDF]

, 2013
A fundamental property of hematopoietic stem cells (HSCs) is the ability to self-renew. This is a complex process involving multiple signal transduction cascades which control the fine balance between self-renewal and differentiation through ...
Copland, M., Sands, W.A., Wheadon, H.
core   +2 more sources

Multi‐Target Drug Design in Alzheimer's Disease Treatment: Emerging Technologies, Advantages, Challenges, and Limitations

Pharmacology Research &Perspectives, Volume 13, Issue 4, August 2025.
ABSTRACT Alzheimer's disease (AD) is a complex and multifactorial neurodegenerative disorder, recognized as the most prevalent form of dementia. It is characterized by multiple pathological processes, including amyloid‐beta accumulation, neurofibrillary tangles, and neuroinflammation. The therapeutic efficacy of traditional single‐target drugs has been
Md Saad Hossain, Md Hamed Hussain
wiley   +1 more source

BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein [PDF]

, 2013
Patients with chronic myeloid leukemia in whom tyrosine kinase inhibitors (TKIs) fail often present mutations in the BCR-ABL catalytic domain. We noticed a lack of substitutions involving 4 amino acids (E286, M318, I360, and D381) that form hydrogen ...
Alessandro Pandini, Chiara Romano, Deininger M., Elena Tirrò, Franca Fraternali, Francesco Di Raimondo, Livia Manzella, Michele Massimino, Nagar B., Paolo G. Vigneri, Pietro Buffa, Shah N. P.   +11 more
core   +1 more source

PARP1 Inhibition Halts EBV+ Lymphoma Progression by Disrupting the EBNA2/MYC Axis

Journal of Medical Virology, Volume 97, Issue 7, July 2025.
ABSTRACT PARP1 has been shown to regulate EBV latency. However, the therapeutic effect of PARP1 inhibitors on EBV+ lymphomagenesis has not yet been explored. Here, we show that PARPi BMN 673 has a potent antitumor effect on EBV‐driven LCL in a mouse xenograft model. We found that PARP1 inhibition induces a dramatic transcriptional reprogramming of LCLs
Lisa Beatrice Caruso, Giorgia Napoletani, Samantha S. Soldan, Davide Maestri, Toshitha Kannan, Sarah Preston‐Alp, Peter Vogel, Andrew Kossenkov, Asher Sobotka, Paul M. Lieberman, Italo Tempera   +10 more
wiley   +1 more source

Chronic Myelogenous Leukemia [PDF]

Deutsches Ärzteblatt international, 2010
The treatment options for bcr-abl positive chronic myelogenous leukemia (CML) include chemotherapy, immune therapy, allogeneic stem cell transplantation, and molecular therapy. The tyrosine kinase inhibitor imatinib was approved for the treatment of CML in 2002.
Justus Duyster, Nikolas von Bubnoff
openaire   +3 more sources

Polypept(o)ide‐Based Core–Shell Bottlebrush Polymers: A Versatile Platform for Drug Encapsulation

Macromolecular Bioscience, Volume 25, Issue 7, July 2025.
This study developed polypept(o)ide‐based core–shell brushes (CSBs) with tunable sizes (Rh: 17–70 nm) for hydrophobic drug delivery. CSBs achieved 10% dasatinib loading through π–π interactions, enabling sustained release over 72 h. Notably, CSB‐dasatinib complexes showed comparable cell viability reduction to the free drug in U‐87 MG cells ...
Bonan Zhao, Jingyuan Wei, Rüdiger Berger, Lin Jian, Kaloian Koynov, Heyang Zhang, Matthias Barz   +6 more
wiley   +1 more source